V.M. Richon
DeWitt Wallace Research Laboratory
Memorial Sloan-Kettering Cancer Center
New York
New York 10021
USA
Name/email consistency: high
- Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Richon, V.M., Zhou, X., Rifkind, R.A., Marks, P.A. Blood Cells Mol. Dis. (2001)
- Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (2000)
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (1998)
- Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Richon, V.M., Russo, P., Venta-Perez, G., Cordon-Cardo, C., Rifkind, R.A., Marks, P.A. Cancer Res. (1997)
- Changes in E2F DNA-binding activity during induced erythroid differentiation. Richon, V.M., Venta-Perez, G. Cell Growth Differ. (1996)